Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00658528
Other study ID # E3810-G000-301
Secondary ID 2007-005570-32
Status Completed
Phase Phase 3
First received April 9, 2008
Last updated November 19, 2015
Start date February 2008
Est. completion date January 2010

Study information

Verified date November 2015
Source Eisai Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease (GERD).


Description:

This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabeprazole ER 50 mg or Esomeprazole 40 mg for the treatment of moderate to severe erosive GERD.


Recruitment information / eligibility

Status Completed
Enrollment 1061
Est. completion date January 2010
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility KEY INCLUSION CRITERIA:

1. Male or female, ages 18 to 75 years.

2. History of GERD symptoms for at least 3 months immediately before screening.

3. Heartburn for at least 2 days a week for at least 1 month before screening.

4. Esophageal erosions of Los Angeles (LA) grades C or D based on EGD taken within 14 days prior to enrollment.

5. Subjects who are H. pylori negative based on a screening test.

6. Females should be either of non-childbearing potential or of childbearing potential. Females of childbearing potential must have negative pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of contraception.

7. Subjects must be able to read, write, and understand the language of the symptom diary.

KEY EXCLUSION CRITERIA:

1. Current or a history of esophageal motility disorders.

2. Current or a history of Barrett's esophagus. Current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications).

3. Current or a history of Zollinger-Ellison syndrome and other acid hypersecretory conditions, or current gastric or duodenal ulcer.

4. Current or a history of cancer, with the exception of fully excised skin basal cell carcinoma.

5. Inflammatory bowel disease.

6. Unstable diabetes mellitus.

7. History of esophageal, gastric and duodenal surgery except simple suturing of an ulcer.

8. Subjects who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral steroids (->;= 20 mg/day prednisone or equivalent), or aspirin (->; 325 mg/day).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Rabeprazole sodium
Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
Esomeprazole
Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Eisai Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Bulgaria,  Canada,  Chile,  Croatia,  Estonia,  France,  Germany,  Hungary,  India,  Latvia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:
Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).
Grade A: One or more mucosal breaks not more than 5 mm in maximum length. Grade B: One or more mucosal breaks more than 5 mm in maximum length, but not continuous between the tops of 2 mucosal folds.
Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.
Gread D: Mucosal breaks involving at least 75% of the esophageal circumference.
Baseline and Week 8 No
Primary Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:
Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).
Grade A: One or more mucosal breaks not more than 5 mm in maximum length. Grade B: One or more mucosal breaks more than 5 mm in maximum length, but not continuous between the tops of 2 mucosal folds.
Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.
Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.
Baseline and Week 4 No
Secondary Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4 During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of hearburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days. Week 4 No
See also
  Status Clinical Trial Phase
Completed NCT03561883 - Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) Phase 3
Completed NCT01406210 - RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol N/A
Completed NCT02555852 - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia N/A
Terminated NCT01327963 - Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study N/A
Completed NCT01570842 - Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury N/A
Completed NCT02141711 - TAK-438 - Safety, Blood Levels & Effects of Repeated Doses Phase 1
Terminated NCT00587275 - Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI Phase 2
Completed NCT00228527 - Esomeprazole for Treatment of GERD in Pediatric Patients Phase 4
Completed NCT00261300 - Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708) Phase 3
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Completed NCT00795093 - Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US N/A
Completed NCT00394472 - Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients Phase 2
Completed NCT00574925 - Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Phase 4
Terminated NCT02749071 - An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux N/A
Recruiting NCT01129713 - Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE. Phase 1/Phase 2
Completed NCT00734747 - Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD) Phase 3
Completed NCT00312806 - Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341) Phase 3
Not yet recruiting NCT05579587 - Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
Recruiting NCT02366169 - Medigus Ultrasonic Surgical Endostapler (MUSE) Registry N/A
Completed NCT01374074 - Racial Disparity in Barrett's Esophagus N/A